EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Targeting neuraminidase: the next frontier for broadly protective influenza vaccines

Nicholas C Wu, Ali H Ellebedy

Trends in Immunology · 2024-01 · 45 (1) · 11-19

DOI: 10.1016/j.it.2023.11.001 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Immunology, 2024-01. Verfasst von Nicholas C Wu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA; Center for Biophysics and Quantitative Biology, Univer…. Hauptthemen laut MEDLINE: Influenza Vaccines, Orthomyxoviridae Infections, Influenza A Virus, H1N1 Subtype, Influenza, Human. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCCIH NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current seasonal influenza vaccines, which mainly target hemagglutinin (HA), require annual updates due to the continuous antigenic drift of the influenza virus. Developing an influenza vaccine with increased breadth of protection will have significant public health benefits. The recent discovery of broadly protective antibodies to neuraminidase (NA) has provided important insights into developing a universal influenza vaccine, either by improving seasonal influenza vaccines or designing novel immunogens. However, further in-depth molecular characterizations of NA antibody responses are warranted to fully leverage broadly protective NA antibodies for influenza vaccine designs. Overall, we posit that focusing on NA for influenza vaccine development is synergistic with existing efforts targeting HA, and may represent a cost-effective approach to generating a broadly protective influenza vaccine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesOrthomyxoviridae InfectionsInfluenza A Virus, H1N1 SubtypeInfluenza, HumanHumansNeuraminidaseAntibodies, Viral

Stichwörter der Autor:innen

antibodyimmunogen designinfluenza virusneuraminidasevaccine

Substanzen

Influenza VaccinesNeuraminidaseAntibodies, Viral

Autor:innen und Institutionen

  • Department of Biochemistry, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA; Center for Biophysics and Quantitative Biology, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA; Carl R. W…
  • Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA; Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, St. Louis, M…

Förderung

  • NIAID NIH HHS
  • NCCIH NIH HHS
  • National Institutes of Health
  • AbbVie

Zitieren

APA

Wu, N. C., & Ellebedy, A. H. (2024). Targeting neuraminidase: the next frontier for broadly protective influenza vaccines. Trends in Immunology, 45(1), 11-19. https://doi.org/10.1016/j.it.2023.11.001

Vancouver

Wu NC, Ellebedy AH. Targeting neuraminidase: the next frontier for broadly protective influenza vaccines. Trends in Immunology. 2024;45(1):11-19. doi:10.1016/j.it.2023.11.001

BibTeX
@article{Wu2024,
  author = {Wu, Nicholas C and Ellebedy, Ali H},
  title = {Targeting neuraminidase: the next frontier for broadly protective influenza vaccines},
  journal = {Trends in Immunology},
  year = {2024},
  volume = {45},
  number = {1},
  pages = {11--19},
  doi = {10.1016/j.it.2023.11.001}
}
Kostenlos starten →